This column was originally published on RealMoney on July 13 at 9:26 a.m. EDT.
Whenever I see the "Oil's up, so the market's down" headlines, I make it a point to see if that correlation has any factual basis.
Like many quick, intuitive explanations, it does not.
As you can see by the chart below, it's not that there's no correlation between the two. There is a correlation.
But at least in the past three-plus years the correlation has been positive, not negative.
I don't know that I'm particularly rooting for oil prices to keep going up, but so far, that rise seems to have little detrimental effect on the market.
Today, charts for the
Wind River Systems
And that is the final word from St. Andrews, where the golf gods have a sick brand of humor.
For months, I was Mr. Fairways-and-Greens, but couldn't knock down a putt.
Then my swing goes on hiatus, but I become Mr. Up-and-Down.
Today, my swing returned ... as did my hands of stone. Yes, it is a cruel game.
Please note that due to factors including low market capitalization and/or insufficient public float, we consider BioMarin Pharmaceutical and ENGlobal to be small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.
Charts produced by TC2000, which is a registered trademark of
Worden Brothers Inc.
P.S. from TheStreet.com Editor-in-Chief, Dave Morrow:
It's always been my opinion that it pays to have more -- not fewer -- expert market views and analyses when you're making investing or trading decisions. That's why I recommend you take advantage of our
premium Web site, where you'll get in-depth commentary
money-making strategies from over 50 Wall Street pros, including Jim Cramer. Take my advice --
Gary B. Smith is a freelance writer who trades for his own account from his Maryland home using technical analysis. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks.
Smith writes a daily technical analysis column for RealMoney.com and also produces a daily premium product for TheStreet.com called The Chartman's Top Stocks --
click here for a free two-week trial. While Gary cannot provide investment advice or recommendations, he appreciates your feedback;
to send him an email.